Claims for Patent: 8,911,778

Summary for Patent: 8,911,778

Title:	Pellet formulation for the treatment of the intestinal tract
Abstract:	An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s):	Otterbeck; Norbert (Uberlingen, DE), Gruber; Peter (Merzhausen, DE)
Assignee:	Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:	13/566,905
Patent Claims:	1. A controlled release pellet formulation comprising: homogeneously dispersed 5-aminosalicyclic acid in a polymer matrix, wherein the polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluid; and an enteric coating; wherein, when administered to humans, the average cumulative fecal excretion of 5-aminosalicyclic acid is greater than 250 mg. 2. The controlled release pellet formulation of claim 1, wherein the average cumulative fecal excretion is measured approximately 72 hours after administration. 3. The controlled release pellet formulation of claim 2, wherein the average cumulative fecal excretion of 5-aminosalicyclic acid is greater than 280 mg. 4. The controlled release pellet formulation of claim 2, wherein the average cumulative fecal excretion of acetyl-5-aminosalicyclic acid is greater than 330 mg. 5. The controlled release pellet formulation of claim 4, wherein the average cumulative fecal excretion of acetyl-5-aminosalicyclic acid is greater than 360 mg. 6. The controlled release formulation of claim 1, wherein the polymer matrix comprises at least 1% by weight of the total weight of the core. 7. The controlled release formulation of claim 6, wherein the polymer matrix comprises poly(ethyl acrylate, methyl methacrylate) or poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride). 8. The controlled release formulation of claim 1, wherein the controlled release formulation is used for the treatment of recurrence of inflammatory intestinal disorders, formation of polyps, intestinal cancer, colorectal polyps, or colorectal cancer. 9. The controlled release formulation of claim 8, wherein the inflammatory intestinal disorder comprise Crohn's disease or ulcerative colitis. 10. The controlled release formulation of claim 1, wherein the controlled release formulation is used for the maintenance of remission of ulcerative colitis. 11. A controlled release pellet formulation comprising: homogeneously dispersed 5-aminosalicyclic acid in a polymer matrix, wherein the polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluid; and an enteric coating; wherein, when administered to humans, the average cumulative fecal excretion of 5-aminosalicyclic acid is about 25% higher than 5-aminosalicyclic acid in the form of enteric tablets. 12. The controlled release formulation of claim 11, the average cumulative fecal excretion of 5-aminosalicyclic acid is about 29% higher than 5-aminosalicyclic acid in the form of enteric tablets. 13. The controlled release formulation of claim 12, wherein the average cumulative fecal excretion of acetyl-5-aminosalicyclic acid is about 40% higher than acetyl-5-aminosalicyclic acid produced from 5-aminosalicyclic acid in the form of enteric tablets. 14. The controlled release formulation of claim 13, wherein the average cumulative fecal excretion of acetyl-5-aminosalicyclic acid is about 44% higher than acetyl-5-aminosalicyclic acid produced from 5-aminosalicyclic acid in the form of enteric tablets. 15. The controlled release formulation of claim 11, wherein the polymer matrix comprises at least 1% by weight of the total weight of the core. 16. The controlled release formulation of claim 15, wherein the polymer matrix comprises poly(ethyl acrylate, methyl methacrylate) or poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride). 17. The controlled release formulation of claim 11, wherein the controlled release formulation is used for the treatment of recurrence of inflammatory intestinal disorders, formation of polyps, intestinal cancer, colorectal polyps, or colorectal cancer. 18. The controlled release formulation of claim 17, wherein the inflammatory intestinal disorder comprise Crohn's disease or ulcerative colitis. 19. The controlled release formulation of claim 11, wherein the controlled release formulation is used for the maintenance of remission of ulcerative colitis.